Proton beam therapy indications in the Kingdom of Saudi Arabia: A SARO clinical practice guideline.
Uložené v:
| Názov: | Proton beam therapy indications in the Kingdom of Saudi Arabia: A SARO clinical practice guideline. |
|---|---|
| Autori: | Aljabab SA; From the Radiation Oncology Unit (Aljabab, Alayed), College of Medicine, King Saud University; from the Oncology Center (Aljabab, Alayed), King Saud University Medical City; from the Department of Radiation Oncology, (Aldehaim, S. Alghamdi) King Faisal Specialist Hospital and Research Center; from the College of Medicine (Aldehaim), Alfaisal University; from the Radiation Oncology (AlHussain), Comprehensive Cancer Center, King Fahad Medical City, Riyadh; from the Department of Radiology (Bahadur), King Abdulaziz University Hospital; from Faulty of Medicine (Bahadur), King Abdulaziz University; from Radiation Oncology (Alomary, M. Alghamdi), Princess Norah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, from the College of Medicine (Alomary, M. Alghamdi), King Saud Bin Abdulaziz University for Health Sciences; from the Radiation Oncology Section (Balbaid), Oncology Department, King Faisal Specialist Hospital and Research Center, Jeddah; from the Radiation Oncology Unit (Al Othman), Oncology Division, Johns Hopkins Aramco Healthcare, Dhahran, Kingdom of Saudi Arabia., Aldehaim MA; From the Radiation Oncology Unit (Aljabab, Alayed), College of Medicine, King Saud University; from the Oncology Center (Aljabab, Alayed), King Saud University Medical City; from the Department of Radiation Oncology, (Aldehaim, S. Alghamdi) King Faisal Specialist Hospital and Research Center; from the College of Medicine (Aldehaim), Alfaisal University; from the Radiation Oncology (AlHussain), Comprehensive Cancer Center, King Fahad Medical City, Riyadh; from the Department of Radiology (Bahadur), King Abdulaziz University Hospital; from Faulty of Medicine (Bahadur), King Abdulaziz University; from Radiation Oncology (Alomary, M. Alghamdi), Princess Norah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, from the College of Medicine (Alomary, M. Alghamdi), King Saud Bin Abdulaziz University for Health Sciences; from the Radiation Oncology Section (Balbaid), Oncology Department, King Faisal Specialist Hospital and Research Center, Jeddah; from the Radiation Oncology Unit (Al Othman), Oncology Division, Johns Hopkins Aramco Healthcare, Dhahran, Kingdom of Saudi Arabia., AlHussain HA; From the Radiation Oncology Unit (Aljabab, Alayed), College of Medicine, King Saud University; from the Oncology Center (Aljabab, Alayed), King Saud University Medical City; from the Department of Radiation Oncology, (Aldehaim, S. Alghamdi) King Faisal Specialist Hospital and Research Center; from the College of Medicine (Aldehaim), Alfaisal University; from the Radiation Oncology (AlHussain), Comprehensive Cancer Center, King Fahad Medical City, Riyadh; from the Department of Radiology (Bahadur), King Abdulaziz University Hospital; from Faulty of Medicine (Bahadur), King Abdulaziz University; from Radiation Oncology (Alomary, M. Alghamdi), Princess Norah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, from the College of Medicine (Alomary, M. Alghamdi), King Saud Bin Abdulaziz University for Health Sciences; from the Radiation Oncology Section (Balbaid), Oncology Department, King Faisal Specialist Hospital and Research Center, Jeddah; from the Radiation Oncology Unit (Al Othman), Oncology Division, Johns Hopkins Aramco Healthcare, Dhahran, Kingdom of Saudi Arabia., Bahadur YA; From the Radiation Oncology Unit (Aljabab, Alayed), College of Medicine, King Saud University; from the Oncology Center (Aljabab, Alayed), King Saud University Medical City; from the Department of Radiation Oncology, (Aldehaim, S. Alghamdi) King Faisal Specialist Hospital and Research Center; from the College of Medicine (Aldehaim), Alfaisal University; from the Radiation Oncology (AlHussain), Comprehensive Cancer Center, King Fahad Medical City, Riyadh; from the Department of Radiology (Bahadur), King Abdulaziz University Hospital; from Faulty of Medicine (Bahadur), King Abdulaziz University; from Radiation Oncology (Alomary, M. Alghamdi), Princess Norah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, from the College of Medicine (Alomary, M. Alghamdi), King Saud Bin Abdulaziz University for Health Sciences; from the Radiation Oncology Section (Balbaid), Oncology Department, King Faisal Specialist Hospital and Research Center, Jeddah; from the Radiation Oncology Unit (Al Othman), Oncology Division, Johns Hopkins Aramco Healthcare, Dhahran, Kingdom of Saudi Arabia., Alomary IS; From the Radiation Oncology Unit (Aljabab, Alayed), College of Medicine, King Saud University; from the Oncology Center (Aljabab, Alayed), King Saud University Medical City; from the Department of Radiation Oncology, (Aldehaim, S. Alghamdi) King Faisal Specialist Hospital and Research Center; from the College of Medicine (Aldehaim), Alfaisal University; from the Radiation Oncology (AlHussain), Comprehensive Cancer Center, King Fahad Medical City, Riyadh; from the Department of Radiology (Bahadur), King Abdulaziz University Hospital; from Faulty of Medicine (Bahadur), King Abdulaziz University; from Radiation Oncology (Alomary, M. Alghamdi), Princess Norah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, from the College of Medicine (Alomary, M. Alghamdi), King Saud Bin Abdulaziz University for Health Sciences; from the Radiation Oncology Section (Balbaid), Oncology Department, King Faisal Specialist Hospital and Research Center, Jeddah; from the Radiation Oncology Unit (Al Othman), Oncology Division, Johns Hopkins Aramco Healthcare, Dhahran, Kingdom of Saudi Arabia., Al Othman MO; From the Radiation Oncology Unit (Aljabab, Alayed), College of Medicine, King Saud University; from the Oncology Center (Aljabab, Alayed), King Saud University Medical City; from the Department of Radiation Oncology, (Aldehaim, S. Alghamdi) King Faisal Specialist Hospital and Research Center; from the College of Medicine (Aldehaim), Alfaisal University; from the Radiation Oncology (AlHussain), Comprehensive Cancer Center, King Fahad Medical City, Riyadh; from the Department of Radiology (Bahadur), King Abdulaziz University Hospital; from Faulty of Medicine (Bahadur), King Abdulaziz University; from Radiation Oncology (Alomary, M. Alghamdi), Princess Norah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, from the College of Medicine (Alomary, M. Alghamdi), King Saud Bin Abdulaziz University for Health Sciences; from the Radiation Oncology Section (Balbaid), Oncology Department, King Faisal Specialist Hospital and Research Center, Jeddah; from the Radiation Oncology Unit (Al Othman), Oncology Division, Johns Hopkins Aramco Healthcare, Dhahran, Kingdom of Saudi Arabia., Alghamdi MA; From the Radiation Oncology Unit (Aljabab, Alayed), College of Medicine, King Saud University; from the Oncology Center (Aljabab, Alayed), King Saud University Medical City; from the Department of Radiation Oncology, (Aldehaim, S. Alghamdi) King Faisal Specialist Hospital and Research Center; from the College of Medicine (Aldehaim), Alfaisal University; from the Radiation Oncology (AlHussain), Comprehensive Cancer Center, King Fahad Medical City, Riyadh; from the Department of Radiology (Bahadur), King Abdulaziz University Hospital; from Faulty of Medicine (Bahadur), King Abdulaziz University; from Radiation Oncology (Alomary, M. Alghamdi), Princess Norah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, from the College of Medicine (Alomary, M. Alghamdi), King Saud Bin Abdulaziz University for Health Sciences; from the Radiation Oncology Section (Balbaid), Oncology Department, King Faisal Specialist Hospital and Research Center, Jeddah; from the Radiation Oncology Unit (Al Othman), Oncology Division, Johns Hopkins Aramco Healthcare, Dhahran, Kingdom of Saudi Arabia., Alghamdi AS; From the Radiation Oncology Unit (Aljabab, Alayed), College of Medicine, King Saud University; from the Oncology Center (Aljabab, Alayed), King Saud University Medical City; from the Department of Radiation Oncology, (Aldehaim, S. Alghamdi) King Faisal Specialist Hospital and Research Center; from the College of Medicine (Aldehaim), Alfaisal University; from the Radiation Oncology (AlHussain), Comprehensive Cancer Center, King Fahad Medical City, Riyadh; from the Department of Radiology (Bahadur), King Abdulaziz University Hospital; from Faulty of Medicine (Bahadur), King Abdulaziz University; from Radiation Oncology (Alomary, M. Alghamdi), Princess Norah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, from the College of Medicine (Alomary, M. Alghamdi), King Saud Bin Abdulaziz University for Health Sciences; from the Radiation Oncology Section (Balbaid), Oncology Department, King Faisal Specialist Hospital and Research Center, Jeddah; from the Radiation Oncology Unit (Al Othman), Oncology Division, Johns Hopkins Aramco Healthcare, Dhahran, Kingdom of Saudi Arabia., Alayed YM; From the Radiation Oncology Unit (Aljabab, Alayed), College of Medicine, King Saud University; from the Oncology Center (Aljabab, Alayed), King Saud University Medical City; from the Department of Radiation Oncology, (Aldehaim, S. Alghamdi) King Faisal Specialist Hospital and Research Center; from the College of Medicine (Aldehaim), Alfaisal University; from the Radiation Oncology (AlHussain), Comprehensive Cancer Center, King Fahad Medical City, Riyadh; from the Department of Radiology (Bahadur), King Abdulaziz University Hospital; from Faulty of Medicine (Bahadur), King Abdulaziz University; from Radiation Oncology (Alomary, M. Alghamdi), Princess Norah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, from the College of Medicine (Alomary, M. Alghamdi), King Saud Bin Abdulaziz University for Health Sciences; from the Radiation Oncology Section (Balbaid), Oncology Department, King Faisal Specialist Hospital and Research Center, Jeddah; from the Radiation Oncology Unit (Al Othman), Oncology Division, Johns Hopkins Aramco Healthcare, Dhahran, Kingdom of Saudi Arabia., Balbaid AA; From the Radiation Oncology Unit (Aljabab, Alayed), College of Medicine, King Saud University; from the Oncology Center (Aljabab, Alayed), King Saud University Medical City; from the Department of Radiation Oncology, (Aldehaim, S. Alghamdi) King Faisal Specialist Hospital and Research Center; from the College of Medicine (Aldehaim), Alfaisal University; from the Radiation Oncology (AlHussain), Comprehensive Cancer Center, King Fahad Medical City, Riyadh; from the Department of Radiology (Bahadur), King Abdulaziz University Hospital; from Faulty of Medicine (Bahadur), King Abdulaziz University; from Radiation Oncology (Alomary, M. Alghamdi), Princess Norah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, from the College of Medicine (Alomary, M. Alghamdi), King Saud Bin Abdulaziz University for Health Sciences; from the Radiation Oncology Section (Balbaid), Oncology Department, King Faisal Specialist Hospital and Research Center, Jeddah; from the Radiation Oncology Unit (Al Othman), Oncology Division, Johns Hopkins Aramco Healthcare, Dhahran, Kingdom of Saudi Arabia. |
| Zdroj: | Saudi medical journal [Saudi Med J] 2025 Nov; Vol. 46 (11), pp. 1280-1299. |
| Spôsob vydávania: | Journal Article; Practice Guideline |
| Jazyk: | English |
| Informácie o časopise: | Publisher: Medical Services Department, Saudi Arabian Armed Forces, Ministry Of Defence And Aviation Country of Publication: Saudi Arabia NLM ID: 7909441 Publication Model: Print Cited Medium: Internet ISSN: 1658-3175 (Electronic) Linking ISSN: 03795284 NLM ISO Abbreviation: Saudi Med J Subsets: MEDLINE |
| Imprint Name(s): | Publication: Riyadh : Medical Services Department, Saudi Arabian Armed Forces, Ministry Of Defence And Aviation Original Publication: Riyadh, Saudi Arabia, Riyadh Al-Kharj Hospital Programme. |
| Výrazy zo slovníka MeSH: | Proton Therapy*/standards , Proton Therapy*/methods , Neoplasms*/radiotherapy , Practice Guidelines as Topic*, Humans ; Saudi Arabia |
| Abstrakt: | Objectives: To update the national guidelines for proton therapy to reflect the evolving literature. The Saudi Particle Therapy Centre is making efforts to establish proton therapy services in the Kingdom of Saudi Arabia. Methods: The Saudi Particle Therapy Center collaborated with the Saudi Association of Radiation Oncology to formulate a panel of radiation oncologists with proton therapy experience to refine and update our previous publication. The recommendation level was based on the overall evidence using a 4-grade scale following the World Health Organization quality of evidence recommendations. These updates focus on summarizing the literature and the level of recommendation for each disease site. The Panel identified key clinical questions to ensure that the guidelines were evidence-based, followed by a comprehensive literature review of PubMed, EMBASE, and other academic databases. Results: The Panel reported that the body of evidence favored proton therapy for specific indications, including ocular tumors, skull and spine tumors, oropharyngeal cancer, hepatocellular carcinoma, specific genetic syndromes and mutations, pediatric rhabdomyosarcoma, pediatric central nervous system malignancies, tumors of the paranasal sinuses/nasal cavity, and for re-irradiation of all sites when curative treatment was intended. In addition, proton therapy may be considered at other sites when photon therapy exceeds the acceptable dose constraints for critical structures. Conclusion: The Panel did not recommend the routine use of proton therapy for all cancers. Each case should be assessed individually following a multidisciplinary review and expert consultation while accounting for financial, logistical, and patient-specific factors. (Copyright: © Saudi Medical Journal.) |
| References: | Pediatr Blood Cancer. 2021 Jul;68(7):e28941. (PMID: 33565257) Anticancer Res. 2015 Mar;35(3):1757-62. (PMID: 25750339) Am J Clin Oncol. 2021 Jun 1;44(6):269-274. (PMID: 33852456) Int J Radiat Oncol Biol Phys. 2021 Feb 1;109(2):441-448. (PMID: 32946965) J Clin Oncol. 2018 Jun 20;36(18):1813-1822. (PMID: 29293386) Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1405-11. (PMID: 16029800) J Thorac Oncol. 2017 Feb;12(2):281-292. (PMID: 27826034) Neuro Oncol. 2013 Nov;15(11):1552-9. (PMID: 24101739) Neurosurg Clin N Am. 2000 Oct;11(4):627-38. (PMID: 11082173) Neuro Oncol. 2022 Jun 1;24(6):1010-1019. (PMID: 34788463) Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):865-71. (PMID: 22138457) J Neurooncol. 1990 Dec;9(3):225-9. (PMID: 2086737) Acta Oncol. 2013 Apr;52(3):498-505. (PMID: 23477361) Radiat Oncol. 2019 Jul 10;14(1):122. (PMID: 31291969) Radiother Oncol. 2013 Aug;108(2):209-14. (PMID: 23891102) Adv Radiat Oncol. 2021 Jun 24;6(5):100744. (PMID: 34646965) Radiother Oncol. 2019 Jun;135:147-152. (PMID: 31015161) Int J Radiat Oncol Biol Phys. 2021 Mar 1;109(3):726-735. (PMID: 33243479) Blood. 2018 Oct 18;132(16):1635-1646. (PMID: 30108066) Br J Radiol. 2014 Jan;87(1033):20130512. (PMID: 24288399) Cancer. 2023 Nov 15;129(22):3554-3563. (PMID: 37503907) J Clin Oncol. 2018 Oct 1;36(28):2854-2862. (PMID: 30118397) Cancers (Basel). 2021 Oct 15;13(20):. (PMID: 34680328) Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):484-90. (PMID: 23523326) Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):181-189. (PMID: 26372435) Clin Transl Radiat Oncol. 2021 Feb 04;27:126-131. (PMID: 33659716) Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):386-395. (PMID: 27084656) Clin Oncol (R Coll Radiol). 2023 Jun;35(6):347-350. (PMID: 36933970) Cancer Res. 1958 Feb;18(2):121-34. (PMID: 13511365) Int J Part Ther. 2020 Winter;6(3):1-12. (PMID: 32582809) Radiat Oncol. 2020 Feb 13;15(1):34. (PMID: 32054496) Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1039-45. (PMID: 20888707) Int J Radiat Oncol Biol Phys. 2020 Aug 1;107(5):986-995. (PMID: 32353390) Int J Radiat Oncol Biol Phys. 2020 Apr 1;106(5):968-976. (PMID: 31987977) Lancet Oncol. 2016 Mar;17(3):287-298. (PMID: 26830377) Pediatr Int. 2015 Aug;57(4):567-71. (PMID: 25754294) Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):277-84. (PMID: 23433794) Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):667-676. (PMID: 29280461) Int J Part Ther. 2016 Fall;3(2):320-326. (PMID: 28989947) Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):512-20. (PMID: 17084540) Strahlenther Onkol. 1999 Jun;175 Suppl 2:57-63. (PMID: 10394399) Neuro Oncol. 2021 Jan 30;23(1):134-143. (PMID: 32592583) Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):1008-16. (PMID: 11958896) Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1107-14. (PMID: 24267972) J Clin Oncol. 2019 Oct 20;37(30):2778-2785. (PMID: 31449469) JAMA Netw Open. 2023 Jan 3;6(1):e2250607. (PMID: 36689229) Int J Part Ther. 2016 Mar;2(4):533-543. (PMID: 31772965) Radiat Oncol. 2016 Feb 27;11:32. (PMID: 26922239) Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):979-84. (PMID: 20888140) Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):831-6. (PMID: 19304408) Cancer. 1982 Feb 15;49(4):759-72. (PMID: 6895713) Cancer. 2011 Oct 15;117(20):4707-13. (PMID: 21437893) Radiat Oncol. 2020 Jun 30;15(1):159. (PMID: 32605627) Acta Oncol. 2016 Sep - Oct;55(9-10):1132-1138. (PMID: 27332881) Int J Radiat Oncol Biol Phys. 2021 Jul 01;110(3):815-820. (PMID: 33508372) Spine (Phila Pa 1976). 2013 Jul 1;38(15):E930-6. (PMID: 23609202) Surg Oncol. 2021 Sep;38:101638. (PMID: 34340196) Int J Part Ther. 2018 Winter;4(3):1-11. (PMID: 31773009) J Hepatol. 2021 Mar;74(3):603-612. (PMID: 33031846) Clin Breast Cancer. 2011 Aug;11(4):241-5. (PMID: 21729673) Radiother Oncol. 2017 Aug;124(2):271-276. (PMID: 28697854) Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):73-86. (PMID: 30797890) Front Oncol. 2019 Oct 01;9:987. (PMID: 31632918) Ann Oncol. 2017 Sep 01;28(9):2179-2184. (PMID: 28911093) Ann Surg Oncol. 2020 Jun;27(6):1721-1723. (PMID: 32246307) J Neurooncol. 2015 May;123(1):123-8. (PMID: 25859843) Int J Mol Sci. 2021 Jul 02;22(13):. (PMID: 34281212) Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):635-42. (PMID: 21377294) World J Radiol. 2016 Aug 28;8(8):735-42. (PMID: 27648167) Neuro Oncol. 2016 Feb;18(2):236-43. (PMID: 26323608) J Clin Oncol. 2020 Feb 10;38(5):454-461. (PMID: 31774710) BMJ Open. 2019 Oct 15;9(10):e025556. (PMID: 31619413) J Neurosurg Spine. 2015 Dec;23(6):788-97. (PMID: 26340383) Clin Neurol Neurosurg. 2018 Nov;174:233-238. (PMID: 30292166) Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):460-6. (PMID: 19427743) Int J Clin Oncol. 2015 Jun;20(3):447-54. (PMID: 25135461) Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):30-41. (PMID: 27325480) Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):494-500. (PMID: 15890592) Radiother Oncol. 2016 Jul;120(1):48-55. (PMID: 27342249) Cancer. 2020 Aug 1;126(15):3560-3568. (PMID: 32426866) J Neurol Surg B Skull Base. 2014 Feb;75(1):53-7. (PMID: 24498590) J Clin Oncol. 2015 Jul 20;33(21):2345-52. (PMID: 26014290) N Engl J Med. 2018 Dec 13;379(24):2342-2350. (PMID: 30280658) Acta Oncol. 2020 Oct;59(10):1235-1239. (PMID: 32421456) Sarcoma. 2022 Mar 19;2022:5540615. (PMID: 35345672) JAMA Oncol. 2020 Feb 1;6(2):237-246. (PMID: 31876914) Radiother Oncol. 2009 Feb;90(2):208-12. (PMID: 19054586) Adv Radiat Oncol. 2017 Jul 19;2(4):588-596. (PMID: 29204526) Radiother Oncol. 2021 Jul;160:32-39. (PMID: 33839202) Radiother Oncol. 2016 Jul;120(1):163-8. (PMID: 27247053) Pract Radiat Oncol. 2019 May;9(3):179-187. (PMID: 30708133) Radiology. 1946 Nov;47(5):487-91. (PMID: 20274616) Radiother Oncol. 2000 Nov;57(2):143-54. (PMID: 11054518) Clin Genitourin Cancer. 2021 Jun;19(3):255-266.e7. (PMID: 32972877) Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):825-842. (PMID: 28943076) Radiother Oncol. 2019 Jul;136:37-43. (PMID: 31015127) J Clin Oncol. 2020 May 10;38(14):1569-1579. (PMID: 32160096) Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):376-83. (PMID: 25841624) Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):149-156. (PMID: 30684665) Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1419-24. (PMID: 22245209) Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):820-829. (PMID: 29976494) Adv Radiat Oncol. 2018 Apr 13;3(3):314-321. (PMID: 30202800) Cancer. 2008 Apr 1;112(7):1568-74. (PMID: 18278809) Lancet Oncol. 2014 Aug;15(9):1027-38. (PMID: 24980873) Technol Cancer Res Treat. 2013 Feb;12(1):1-9. (PMID: 22775339) J Gastrointest Oncol. 2017 Aug;8(4):665-674. (PMID: 28890817) J Radiat Res. 2015 Nov;56(6):927-37. (PMID: 26386255) Neurosurgery. 2003 Sep;53(3):577-86; discussion 586-8. (PMID: 12943574) Cancer. 2011 Jul 1;117(13):3004-13. (PMID: 21264827) Cancer. 2001 Dec 15;92(12):3012-29. (PMID: 11753979) Radiat Oncol. 2013 Dec 17;8:289. (PMID: 24344645) Acta Oncol. 2011 Aug;50(6):806-16. (PMID: 21767178) Adv Radiat Oncol. 2019 Jul 16;4(4):689-698. (PMID: 31673662) Adv Radiat Oncol. 2023 Aug 18;9(2):101355. (PMID: 38405315) Adv Radiat Oncol. 2024 Feb 06;9(5):101459. (PMID: 38596455) J Pain Symptom Manage. 2016 May;51(5):832-8. (PMID: 26891607) Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e489-96. (PMID: 21497457) Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):64-72. (PMID: 30684667) Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):732-9. (PMID: 19095372) Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):628-34. (PMID: 20385451) Cancer. 2020 Jan 1;126(9):1905-1916. (PMID: 32097507) Medicine (Baltimore). 2016 Mar;95(11):e3113. (PMID: 26986158) Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1367-73. (PMID: 20934266) Neuro Oncol. 2020 Sep 29;22(9):1348-1358. (PMID: 32193546) Radiother Oncol. 2018 Dec;129(3):520-526. (PMID: 30021697) Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):691-8. (PMID: 17011445) Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1323-31. (PMID: 19616740) J Clin Oncol. 2016 Apr 1;34(10):1043-9. (PMID: 26811522) Radiother Oncol. 2020 Jan;142:147-153. (PMID: 31522879) Adv Radiat Oncol. 2020 Oct 14;6(1):100595. (PMID: 33490730) Neuro Oncol. 2016 Jun;18(6):881-7. (PMID: 26688075) Radiother Oncol. 2019 Aug;137:95-101. (PMID: 31082632) Int J Radiat Oncol Biol Phys. 2023 Jul 15;116(4):825-836. (PMID: 36642110) Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1549-57. (PMID: 22270176) J Neurooncol. 2021 Oct;155(1):93-100. (PMID: 34596831) Cancer Sci. 2015 Mar;106(3):217-26. (PMID: 25529563) N Engl J Med. 2013 Mar 14;368(11):987-98. (PMID: 23484825) Cancer. 2015 May 15;121(10):1712-9. (PMID: 25585890) Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):98-103. (PMID: 19910136) Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):501-5. (PMID: 25084608) |
| Contributed Indexing: | Keywords: clinical decision-making; practice guidelines as topic; proton therapy |
| Entry Date(s): | Date Created: 20251112 Date Completed: 20251113 Latest Revision: 20251126 |
| Update Code: | 20251126 |
| PubMed Central ID: | PMC12625664 |
| DOI: | 10.15537/smj.2025.46.11.20250572 |
| PMID: | 41224339 |
| Databáza: | MEDLINE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Objectives: To update the national guidelines for proton therapy to reflect the evolving literature. The Saudi Particle Therapy Centre is making efforts to establish proton therapy services in the Kingdom of Saudi Arabia.<br />Methods: The Saudi Particle Therapy Center collaborated with the Saudi Association of Radiation Oncology to formulate a panel of radiation oncologists with proton therapy experience to refine and update our previous publication. The recommendation level was based on the overall evidence using a 4-grade scale following the World Health Organization quality of evidence recommendations. These updates focus on summarizing the literature and the level of recommendation for each disease site. The Panel identified key clinical questions to ensure that the guidelines were evidence-based, followed by a comprehensive literature review of PubMed, EMBASE, and other academic databases.<br />Results: The Panel reported that the body of evidence favored proton therapy for specific indications, including ocular tumors, skull and spine tumors, oropharyngeal cancer, hepatocellular carcinoma, specific genetic syndromes and mutations, pediatric rhabdomyosarcoma, pediatric central nervous system malignancies, tumors of the paranasal sinuses/nasal cavity, and for re-irradiation of all sites when curative treatment was intended. In addition, proton therapy may be considered at other sites when photon therapy exceeds the acceptable dose constraints for critical structures.<br />Conclusion: The Panel did not recommend the routine use of proton therapy for all cancers. Each case should be assessed individually following a multidisciplinary review and expert consultation while accounting for financial, logistical, and patient-specific factors.<br /> (Copyright: © Saudi Medical Journal.) |
|---|---|
| ISSN: | 1658-3175 |
| DOI: | 10.15537/smj.2025.46.11.20250572 |